Effects of the Δ67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision

Journal of Virology

Volumn 78, Issue 18, 2004, Pages 9987-9997

  Boyer, Paul L ^a   Imamichi, Tomozumi ^b   Sarafianos, Stefan G ^c   Arnold, Edward ^c   Hughes, Stephen H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; DEOXYRIBONUCLEOSIDE TRIPHOSPHATE; NUCLEOSIDE DERIVATIVE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; VIRUS ENZYME; ZIDOVUDINE; ZIDOVUDINE 5' PHOSPHATE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NUCLEOSIDE; PRIMER DNA; RECOMBINANT PROTEIN; VIRUS DNA;

AMINO ACID SUBSTITUTION; ARTICLE; CODON; CONCENTRATION RESPONSE; GENE DELETION; GENE INSERTION; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; OPEN READING FRAME; PRIORITY JOURNAL; VIRUS GENE; VIRUS ISOLATION; VIRUS MUTATION; VIRUS RESISTANCE; ANTIBIOTIC RESISTANCE; BIOLOGICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; ENZYME ACTIVE SITE; ENZYMOLOGY; GENETICS; HUMAN; IN VITRO STUDY; METABOLISM; MUTATION; NUCLEOTIDE SEQUENCE;

AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; BASE SEQUENCE; CATALYTIC DOMAIN; DNA PRIMERS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; MUTATION; NUCLEOSIDES; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE INHIBITORS; ZIDOVUDINE;

EID: 4444355318     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.18.9987-9997.2004     Document Type: Article

References (38)

1. Arion, D., N. Kaushik, S. McCormick, G. Borkow, and M. A. Parniak. 1998. Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′- deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 37:15908-15917.
2. Bofill, M., L. D. Fairbanks, K. Ruckemann, M. Lipman, and H. A. Simmonds. 1995. T-Lymphocytes from AIDS patients are unable to synthesize ribonucleotides de novo in response to mitogenic stimulation. J. Biol. Chem. 270:29690-29697.
3. Boyer, P. L., S. G. Sarafianos, E. Arnold, and S. H. Hughes. 2001. Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. J. Virol. 75:4832-4842.
4. Boyer, P. L., S. G. Sarafianos, E. Arnold, and S. H. Hughes. 2002. Nucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves ATP-mediated excision. J. Virol. 76:9143-9151.
5. Boyer, P. L., S. G. Sarafianos, E. Arnold, and S. H. Hughes. 2002. The M184V mutation reduces the selective excision of zidovudine 5′- monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1. J. Virol. 76:3248-3256.
6. Chamberlain, P. P., J. Ren, C. E. Nichols, L. Douglas, J. Lennerstrand, B. A. Larder, D. I. Stuart, and D. K. Stammers. 2002. Crystal structures of zidovudine- or lamivudine-resistant human immunodeficiency virus type 1 reverse transcriptases containing mutations at codons 41, 184, and 215. J. Virol. 76:10015-10019.
7. Coffin, J. M., S. H. Hughes, and H. E. Varmus (ed.). 1997. Retroviruses. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
8. Fairbanks, L. D., M. Bofill, K. Ruckemann, and H. A. Simmonds. 1995. Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. J. Biol. Chem. 270:29682-29689.
9. Gao, W.-Y., A. Cara, R. C. Gallo, and F. Lori. 1993. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc. Natl. Acad. Sci. USA 90:8925-8928.
10. Giri, J., H. J. Rueda, A. Monticelli, and N. Planes. 2000. Case report of a novel amino acid deletion in codon 67 and T69G substitution in the reverse transcriptase of HIV-1. Antivir. Ther. 5:227-228.
11. Giri, J., R. H. Jaureguli, A. Monticelli, D. A. Pirola, and N. Planes. 2001. Infrequent deletion in 67 codon in HIV reverse transcriptase in antiretroviral treatment failure. Medicina (B. Aires) 61:193-195.
12. Harrigan, P. R., M. D. Miller, P. McKenna, Z. L. Brumme, and B. A. Larder. 2002. Phenotypic susceptibilities to tenofovir in a large panel of clinically derived human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 46:1067-1072.
13. Huang, H., R. Chopra, G. F. Verdine, and S. C. Harrison. 1998. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282:1669-1675.
14. Imamichi, T., S. C. Berg, H. Imamichi, J. C. Lopez, J. A. Metcalf, J. Falloon, and H. C. Lane. 2000. Relative replication fitness of a high-level 3′-azido-3′-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr → Gly) at codon 69. J. Virol. 74:10958-10964.
15. Imamichi, T., T. Sinha, H. Imamichi, Y.-M. Zhang, J. A. Metcalf, J. Falloon, and H. C. Lane. 2000. High-level resistance to 3′-azido-3′- deoxythymidine due to a deletion in the reverse transcriptase gene of human immunodeficiency virus type 1. J. Virol. 74:1023-1028.
16. Imamichi, T., M. A. Murphy, H. Imamichi, and H. C. Lane. 2001. Amino acid deletion at codon 67 and Thr-to-Gly change at codon 69 of human immunodeficiency virus type 1 reverse transcriptase confer novel drug resistant profiles. J. Virol. 75:3988-3992.
17. Kaliki, V., N. K. Day, E. Dinglasan, M. James-Yarish, R. Hitchcock, D. Skapura, A. Chinta, L. Johnson, A. Andreopoulos, A. Rey, R. A. Good, and S. Haraguchi. 2000. Emergence of HIV-1 variants containing codon insertions and deletions in the β3-β4 hairpin loop domain of reverse transcriptase. Immunol. Letts. 74:173-175.
18. Kim, E.-Y., L. Vrang, B. Öberg, and T. C. Merigan. 2001. Anti-HIV type 1 activity of 3′-fluoro-3′deoxythymidine for several different multi-drug-resistant mutants. AIDS Res. Hum. Retrovir. 17:401-407.
19. Lennerstrand, J., D. K. Stammers, and B. A. Larder. 2001. Biochemical mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to stavudine. Antimicrob. Agents Chemother. 45:2144-2146.
20. Margot, N. A., E. Isaacson, I. McGowan, A. Cheng, and M. D. Miller. 2003. Extended treatment with tenofovir disproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses. J. Acquir. Immune Defic. Syndr. 33:15-21.
21. Mas, A., M. Parera, C. Briones, V. Soriano, M. A. Martínez, E. Domingo, and L. Menéndez-Arias. 2000. Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance. EMBO J. 19:5752-5761.
22. Masciari, R., L. Cosco, M. C. Diaco, D. N. Della, T. Ferraro, T. Raimondi, B. Ruperti, and E. Santandrea. 2002. HIV-1: a case of RT67 deletion in a multi-treated non responder patient. New Microbiol. 25:83-88.
23. Maxeiner, H.-G., W. Keulen, R. Schuurman, M. Bijen, L. de Graaf, A. van Wijk, N. Back, M. W. Kline, C. A. B. Boucher, and M. Nijhuis. 2002. Selection of zidovudine resistance mutations and escape of human immunodeficiency virus type 1 from antiretroviral pressure in stavudine-treated pediatric patients. J. Infect. Diseases 185:1070-1076.
24. Meyer, P. R., S. E. Matsuura, A. G. So, and W. A. Scott. 1998. Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc. Natl. Acad. Sci. USA 95:13471-13476.
25. Meyer, P. R., S. E. Matsuura, A. A. Tolun, I. Pfeifer, A. G. So, J. W. Mellors, and W. A. Scott. 2002. Effects of specific zidovudine resistance mutations and substrate structure on nucleotide-dependent primer unblocking by human immunodeficiency type 1 reverse transcriptase. Antimicrob. Agents Chemother. 46:1540-1545.
26. Meyer, P. R., J. Lennerstrand, S. E. Matsuura, B. A. Larder, and W. A. Scott. 2003. Effects of dipeptide insertions between codons 69 and 70 of human immunodeficiency virus type 1 reverse transcriptase on primer unblocking, deoxynucleoside triphosphate inhibition, and DNA chain elongation. J. Virol. 77:3871-3877.
27. Meyer, P. R., S. E. Matsuura, D. Zonarich, R. R. Chopra, E. Pendarvis, H. Z. Bazmi, J. W. Mellors, and W. A. Scott. 2003. Relationship between 3′-azido-3′-deoxythymine resistance and primer unblocking activity in foscarnet-resistant mutants of human immunodeficiency virus type 1 reverse transcriptase. J. Virol. 77:6127-6137.
28. Naeger, L. K., N. A. Margot, and M. D. Miller. 2001. Tenofovir (PMPA) is less susceptible to pyrophosphorolysis and nucleotide-dependent chain-terminator removal than zidovudine or stavudine. Nucleosides Nucleotides Nucleic Acids 20:635-639.
29. Naeger, L. K., N. A. Margot, and M. D. Miller. 2002. ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 46:2179-2184.
30. Ray, A. S., E. Murakami, A. Basavapathruni, J. A. Vaccaro, D. Ulrich, C. K. Chu, R. F. Schinazi, and K. S. Anderson. 2003. Probing the molecular mechanisms of AZT drug resistance mediated by HIV-1 reverse transcriptase using a transient kinetic analysis. Biochemistry 42:8831-8841.
31. Ross, L., M. Johnson, R. G. Ferris, S. A. Short, L. R. Boone, T. E. Melby, R. Lanier, M. Shaefer, and M. St. Clair. 2000. Deletions in the β3-β4 hairpin loop of HIV-1 reverse transcriptase are observed in HIV-1 isolated from subjects during long-term antiviral therapy. J. Hum. Virol. 3:144-149.
32. Ross, L., A. Scarsella, S. Raffanti, K. Henry, S. Becker, R. Fisher, Q. Liao, A. Hirani, N. Graham, M. St. Clair, and J. Hernandez. 2001. Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens. AIDS Res. Hum. Retrovir. 17:1107-1115.
33. Sarafianos, S. G., A. D. Clark, Jr., K. Das, S. Tuske, J. J. Birktoft, P. Ilankumaran, A. R. Ramesha, J. M. Sayer, D. M. Jerina, P. L. Boyer, S. H. Hughes, and E. Arnold. 2002. Structures of HIV-1 reverse transcriptase with pre- and post-translocation AZTMP-terminated DNA. EMBO J. 21:6614-6624.
34. Schinazi, R. F., B. A. Larder, and J. W. Mellors. 2001. Mutations in retroviral genes associated with drug resistance: 2000-2001 update. Int. Antivir. News 8:65-91.
35. Shulman, N. S., M. D. Hughes, M. A. Winters, R. W. Schafer, A. R. Zolopa, N. D. S. Hellman, M. Bates, J. M. Whitcomb, and D. A. Katzenstein. 2002. Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients. J. Acquir. Immune Defic. Syndr. 31:121-127.
36. Tong, W., C.-D. Lu, S. K. Sharma, S. Matsuura, A. G. So, and W. A. Scott. 1997. Nucleotide-induced stable complex formation by HIV-1 reverse transcriptase. Biochemistry 36:5749-5757.
37. Tuske, S., S. G. Sarafiarios, A. D. Clark, Jr., J. Ding, L. K. Naeger, K. L. White, M. D. Miller, C. S. Gibbs, P. L. Boyer, P. Clark, G. Wang, B. L. Gaffney, R. A. Jones, D. M. Jerina, S. H. Hughes, and E. Arnold. 2004. Structures of HIV-1 RT-DNA complexes before and after the incorporation of the anti-AIDS drug tenofovir. Nat. Struct. Mol. Biol. 11:469-474.
38. White, K. L., J. M. Chen, N. A. Margot, T. Wrin, C. J. Petropoulos, L. K. Naeger, S. Swaminathan, and M. D. Miller. 2004. Molecular mechanisms of resistance to tenofovir by HIV-1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations. Antimicrob. Agents Chemother. 48:992-1003.